SHERMAN JEFFREY W purchased $10K of LRMR
SHERMAN JEFFREY W purchased 3,289 shares of Larimar Therapeutics, Inc. (LRMR) at $3.06 on 2026-11-16.
Larimar Therapeutics, Inc.
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for complex rare diseases using a cell-penetrating peptide technology platform. Its lead product candidate, nomlabofusp, is an investigational protein replacement therapy administered by subcutaneous injection. It is designed to deliver frataxin to mitochondria in people with Friedreich’s ataxia, a rare disease associated with insufficient frataxin. Larimar is testing nomlabofusp in clinical studies and is exploring its platform for other rare diseases involving deficiencies or alterations in intracellular molecules. Larimar has completed Phase 1 and Phase 2 studies in adults with Friedreich’s ataxia and a Phase 1 pharmacokinetic study in adolescents. It is conducting an open-label study in adults and adolescents. The company’s work focuses on research and development, intellectual property, and third-party manufacturing capabilities. It intends to commercialize nomlabofusp independently or with third parties if it receives regulatory approval. Larimar is headquartered in Bala Cynwyd, Pennsylvania.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
SHERMAN JEFFREY W purchased 3,289 shares of Larimar Therapeutics, Inc. (LRMR) at $3.06 on 2026-11-16.
Wedbush cut its price target on Larimar Therapeutics (LRMR) to $9 from $11, citing funding concerns, while maintaining an Outperform rating. The stock is up 19% in the past week. The company has $129M in cash, enough to last until late Q2 2027, but faces high cash burn. Wedbush expects BLA acceptance in January and potential fundraising in Q1 2027.
Larimar Therapeutics (LRMR) reported a narrowed Q3 2026 net loss of $31.1M, down from $47.7M a year earlier. The company completed its BLA submission for nomlabofusp, a potential treatment for Friedreich's ataxia, and expects FDA review in early 2027. Cash reserves total $128.7M, with a runway into late Q2 2027. LRMR stock closed at $3.02, up 11.85%.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning LRMR (Larimar Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 3 neutral, and 3 bearish.
Recent LRMR coverage spans insider activity, financial news and regulation.
In the last 30 days, LRMR insiders filed 8 SEC Form 4 transactions — 8 purchases ($392K) and no sales. The most active reporter was Hamilton Thomas Edward with 1 filing.
Small director open-market purchase is mildly supportive sentiment but unlikely to change fundamentals or drive a tradable repricing by itself.
Analyst target cut suggests lower near‑term upside.
The BLA filing introduces a material regulatory catalyst that could lift the stock if the FDA grants accelerated approval.
The filing introduces a new regulatory milestone that could drive the stock higher if the FDA grants accelerated approval.
Insider buying by a director suggests confidence and may create modest buying pressure.
AlphAI scores every news story that mentions LRMR with an AI model for sentiment and relevance, and aggregates insider trades from Larimar Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SHERMAN JEFFREY W purchased 3,289 shares of Larimar Therapeutics, Inc. (LRMR) at $3.06 on 2026-11-16.
Wedbush cut its price target on Larimar Therapeutics (LRMR) to $9 from $11, citing funding concerns, while maintaining an Outperform rating. The stock is up 19% in the past week. The company has $129M in cash, enough to last until late Q2 2027, but faces high cash burn. Wedbush expects BLA acceptance in January and potential fundraising in Q1 2027.
Larimar Therapeutics (LRMR) reported a narrowed Q3 2026 net loss of $31.1M, down from $47.7M a year earlier. The company completed its BLA submission for nomlabofusp, a potential treatment for Friedreich's ataxia, and expects FDA review in early 2027. Cash reserves total $128.7M, with a runway into late Q2 2027. LRMR stock closed at $3.02, up 11.85%.
Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o
Hamilton Thomas Edward purchased 70,000 indirectly-held shares of Larimar Therapeutics, Inc. (LRMR) at $2.67 ($0.19M total) on 2026-11-12.
BEN-MAIMON CAROLE (President and CEO) purchased 18,050 shares of Larimar Therapeutics, Inc. (LRMR) at $2.77 on 2026-11-11.
THOMAS FRANK E purchased 8,000 shares of Larimar Therapeutics, Inc. (LRMR) at $2.72 on 2026-11-11.
Truitt Joseph purchased 3,500 shares of Larimar Therapeutics, Inc. (LRMR) at $2.80 on 2026-11-11.
Harlow John B. Jr. (President and COO) purchased 17,800 shares of Larimar Therapeutics, Inc. (LRMR) at $2.80 on 2026-11-11.
Celano Michael (Chief Financial Officer) purchased 18,460 shares of Larimar Therapeutics, Inc. (LRMR) at $2.71 on 2026-11-11.